CliffBio
small molecule

XIFAXAN

RIFAXIMIN

Loss of exclusivityJuly 2029latest FDA-listed patent expiry
CompanySalix Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameXIFAXAN
Active ingredientRIFAXIMIN
Strength200MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2004
Marketing statusRX

Listed patents

PatentExpiresType
7928115July 2029use U-1121
8193196September 2027substance, product
10703763February 2026use U-2848
8741904February 2026substance, product
8518949February 2026product
9271968February 2026product

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XIFAXAN patent cliff — loss of exclusivity July 2029 | CliffBio